Nat Rev Mol Cell Biol 5:875885 West KA, Castillo SS, Dennis PA (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance
reports consulting fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals, DINORA, ANI/Exeltis, Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications and the National Institutes of Health
(2023) Br J Cancer, 129: 1978.(245)Chang K, et al
PPC developed in eight, nine, and nine patients at the third, fifth, and 10th year in the smoking patients after the onset of CP, the cumulative rates of which were 14.5% (95% CI: 9.519.5%), 16.4% (95% CI: 10.821.9%), and 16.4% (95% CI: 10.821.9%), and in four, five, and 11 patients in the drinking patients, the cumulative rates of which were 5.0% (95% CI: 2.67.4%), 6.3% (95% CI: 3.68.9%), and 11.3% (95% CI: 7.115.4%), while in 105, 126, and 160 patients in the controls, the cumulative rates were 8.8% (95% CI: 7.99.7%), 10.6% (95% CI: 9.611.6%), and 13.5% (95% CI: 12.214.7%), respectively